Earlier this week, iPR Pharmaceuticals, Inc., the owner of NDA for Crestor tablets and AstraZeneca filed a Complaint seeking to block FDA’s approval of ANDAs for generic Crestor ahead of the July 8 date when many in the industry had been anticipating approval.
Read more at the FDA Law Blog.
Filed Under: Drug Discovery
